| Size | Price | Stock | Qty |
|---|---|---|---|
| 2mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| 25mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 250mg |
|
||
| Other Sizes |
|
Purity: ≥98%
AZD3264 (AZD-3264; AZD 3264) is a novel and potent inhibitor of IKK2 (IkappaB Kinase/(IκB) with potential anti-inflammatory and anticancer activity. IKK2 is an enzyme complex that is a part of the signaling pathway for NF-kappaB and NF-κB. For the treatment of inflammatory diseases like RA/rheumatoid arthritis, asthma, and chronic pulmonary obstructive disorder (COPD), AZD3264 is currently undergoing preclinical testing. IKK2 suppression has been identified as a potential therapeutic approach for the management of inflammatory and malignant conditions.
| Targets |
IKK2
|
||
|---|---|---|---|
| ln Vitro |
AZD3264 is a selective IkB-kinase IKK2 inhibitor, which is presently being developed in preclinical studies for the potential treatment of asthma and chronic obstructive pulmonary disease (COPD)[1].
|
||
| ln Vivo |
|
||
| Enzyme Assay |
AZD3264, by inhibiting IKK2, was currently in preclinical development for the potential treatment of inflammatory diseases such as asthma, chronic pulmonary obstructive disorder (COPD) and rheumatoid arthritis.
|
||
| Animal Protocol |
|
||
| References |
| Molecular Formula |
C21N5O4SH23
|
|
|---|---|---|
| Molecular Weight |
441.5
|
|
| Exact Mass |
441.147
|
|
| Elemental Analysis |
C, 57.13; H, 5.25; N, 15.86; O, 14.49; S, 7.26
|
|
| CAS # |
1609281-86-8
|
|
| Related CAS # |
|
|
| PubChem CID |
91666658
|
|
| Appearance |
White to off-white solid powder
|
|
| Density |
1.4±0.1 g/cm3
|
|
| Boiling Point |
614.2±55.0 °C at 760 mmHg
|
|
| Flash Point |
325.2±31.5 °C
|
|
| Vapour Pressure |
0.0±1.8 mmHg at 25°C
|
|
| Index of Refraction |
1.653
|
|
| LogP |
2.08
|
|
| Hydrogen Bond Donor Count |
4
|
|
| Hydrogen Bond Acceptor Count |
7
|
|
| Rotatable Bond Count |
6
|
|
| Heavy Atom Count |
31
|
|
| Complexity |
670
|
|
| Defined Atom Stereocenter Count |
1
|
|
| SMILES |
NC(=O)NC1=C(C(N)=O)C=C(S1)C2C(O[C@H]3CNCC3)=CC(=CC=2)C4=C(C)ON=C4C
|
|
| InChi Key |
NMFIXEFNQPDISY-ZDUSSCGKSA-N
|
|
| InChi Code |
InChI=1S/C21H23N5O4S/c1-10-18(11(2)30-26-10)12-3-4-14(16(7-12)29-13-5-6-24-9-13)17-8-15(19(22)27)20(31-17)25-21(23)28/h3-4,7-8,13,24H,5-6,9H2,1-2H3,(H2,22,27)
|
|
| Chemical Name |
2-(carbamoylamino)-5-[4-(3,5-dimethyl-1,2-oxazol-4-yl)-2-[(3S)-pyrrolidin-3-yl]oxyphenyl]thiophene-3-carboxamide
|
|
| Synonyms |
|
|
| HS Tariff Code |
2934.99.9001
|
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
|
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
|
|||
|---|---|---|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (5.66 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (5.66 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.2650 mL | 11.3250 mL | 22.6501 mL | |
| 5 mM | 0.4530 mL | 2.2650 mL | 4.5300 mL | |
| 10 mM | 0.2265 mL | 1.1325 mL | 2.2650 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
COA